HomeCompareACEHF vs ABBV

ACEHF vs ABBV: Dividend Comparison 2026

ACEHF yields 59.22% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACEHF wins by $23.78M in total portfolio value
10 years
ACEHF
ACEHF
● Live price
59.22%
Share price
$0.00
Annual div
$0.00
5Y div CAGR
18%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.88M
Annual income
$14,609,844.43
Full ACEHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ACEHF vs ABBV

📍 ACEHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACEHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACEHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACEHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACEHF
Annual income on $10K today (after 15% tax)
$5,034.02/yr
After 10yr DRIP, annual income (after tax)
$12,418,367.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ACEHF beats the other by $12,397,311.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACEHF + ABBV for your $10,000?

ACEHF: 50%ABBV: 50%
100% ABBV50/50100% ACEHF
Portfolio after 10yr
$11.99M
Annual income
$7,317,308.10/yr
Blended yield
61.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ACEHF
No analyst data
Altman Z
3.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACEHF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACEHFABBV
Forward yield59.22%3.06%
Annual dividend / share$0.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR18%40.6%
Portfolio after 10y$23.88M$102.3K
Annual income after 10y$14,609,844.43$24,771.77
Total dividends collected$22.86M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ACEHF vs ABBV ($10,000, DRIP)

YearACEHF PortfolioACEHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$17,688$6,988.40$11,550$430.00+$6.1KACEHF
2$32,559$13,632.15$13,472$627.96+$19.1KACEHF
3$62,510$27,672.07$15,906$926.08+$46.6KACEHF
4$125,475$58,589.70$19,071$1,382.55+$106.4KACEHF
5$263,955$129,696.68$23,302$2,095.81+$240.7KACEHF
6$583,316$300,884.02$29,150$3,237.93+$554.2KACEHF
7$1,357,430$733,282.01$37,536$5,121.41+$1.32MACEHF
8$3,334,291$1,881,840.43$50,079$8,338.38+$3.28MACEHF
9$8,665,305$5,097,614.24$69,753$14,065.80+$8.60MACEHF
10$23,881,721$14,609,844.43$102,337$24,771.77+$23.78MACEHF

ACEHF vs ABBV: Complete Analysis 2026

ACEHFStock

PT Ace Hardware Indonesia Tbk, together with its subsidiaries, engages in the retail of household appliances and lifestyle products in Indonesia. It operates through Home Improvement Products, Lifestyle Products, and Toys Products segments. As of December 31, 2021, it operated 216 retail outlets located in Jakarta, Tangerang, Cilegon, Bekasi, Karawang, Bogor, Depok, Cirebon, Bandung, Sumedang, Tasikmalaya, Gresik, Yogyakarta, Semarang, Solo, Purwokerto, Tegal, Surabaya, Malang, Jember, Kediri, Madiun, Aceh, Bali, Medan, Batam, Padang, Pekan Baru, Palembang, Jambi, Bengkulu, Lampung, Balikpapan, Makassar, Banjarmasin, Pontianak, Manado, Maluku, Samarinda, Kupang, Lombok, Kendari, Pangkal Pinang, Mojokerto, Gorontalo, and Riau. The company was formerly known as PT Ace Indoritel Perkakas and changed its name to PT Ace Hardware Indonesia Tbk in August 2001. The company was founded in 1995 and is headquartered in Jakarta, Indonesia. PT Ace Hardware Indonesia Tbk is a subsidiary of PT Kawan Lama Sejahtera.

Full ACEHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ACEHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACEHF vs SCHDACEHF vs JEPIACEHF vs OACEHF vs KOACEHF vs MAINACEHF vs JNJACEHF vs MRKACEHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.